Christian Brander obtained his PhD in Immunology from the University of Bern in 1994 for his studies on T-cell hypersensitivity to Penicillin and work on the mechanisms of exogenous antigen re-presentation on HLA class I. He completed his post-doctoral training at Massachusetts General Hospital in Boston focusing on T cell immunity to HIV and studying the impact that host genetics have on these immune responses. He was Associate Professor at Harvard Medical School before joining ICREA in 2008 with an appointment at the IrsiCaixa AIDS Research Institute to continue his work on cellular immunity to viral infections (HIV, HCV and herpesviruses), especially also in the transplantation setting. He is a co-inventor of the HIV "HTI" immunogen, which is developed clinically by Aelix Therapeutics Inc. where he is a co-founder and CSO. He serves as the scientific director of the HIVACAT program and holds an Associate Professor position at the University of Vic and Central Catalonia.